de Urioste George
Known title: DirectorCIK: 0001270068
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
BZAI Announces Restructuring Plan to Focus on Core Growth. Blaize Holdings disclosed a restructuring plan aimed at concentrating resources on its core growth areas. The company said the move will streamline operations and allocate capital to priority segments. This shift may influence its cost structure and future revenue trajectory. The stock is trading near a long‑standing support level, while analysts keep an average target of $1.80.
Transaction History
| BEAT | ▼ Sell | Open Market | 33,185 | $94K | 12/18/2025 | View on chart |
| BEAT | ▼ Sell | Open Market | 23,961 | $88K | 12/17/2025 | View on chart |
| BZAI | ▲ Buy | Grant | 75,258 | $0 | 12/3/2025 | View on chart |
| BZAI | ▲ Buy | Grant | 94,361 | $0 | 6/28/2025 | View on chart |
| BEAT | ▼ Sell | Open Market | 1,674 | $4K | 9/6/2024 | View on chart |
| BEAT | ▼ Sell | Open Market | 5,500 | $13K | 8/30/2024 | View on chart |
| BEAT | ▼ Sell | Open Market | 2,194 | $5K | 8/27/2024 | View on chart |
| BEAT | ▼ Sell | Open Market | 300 | $714 | 8/26/2024 | View on chart |
| BEAT | ▼ Sell | Open Market | 2,500 | $6K | 8/23/2024 | View on chart |
| BEAT | ▲ Buy | Grant | 33,185 | $0 | 6/12/2024 | View on chart |
| BEAT | ▼ Sell | Open Market | 5,500 | $11K | 9/29/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 8,000 | $16K | 9/28/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 1,834 | $4K | 9/27/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 5,000 | $10K | 9/26/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 2,393 | $5K | 9/22/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 100 | $241 | 9/21/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 883 | $2K | 9/20/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 5,000 | $12K | 9/18/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 4,269 | $10K | 9/15/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 5,000 | $11K | 9/14/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 1,878 | $4K | 9/13/2023 | View on chart |
| BEAT | ▼ Sell | Open Market | 3,122 | $6K | 9/13/2023 | View on chart |
| BEAT | ▲ Buy | Grant | 23,961 | $0 | 7/13/2023 | View on chart |
| BEAT | ▲ Buy | Grant | 55,147 | $0 | 7/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test
HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test. HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.